Fior Markets launched a study titled “Global Asthma Spacers Market by Product (Aerochamber, Optichamber, Volumatic and Inspirease), Distribution Channel (Retail Pharmacy, Hospital Pharmacy and E-commerce), Region” and Global Forecast 2018-2025.

The global asthma spacers market is expected to grow from USD 1440.61 Million in 2017 to USD 2050.19 Million by 2025 at a CAGR of 4.14% during the forecast period from 2018-2025. Government initiatives to reduce the number of cases of asthma, increasing prevalence of the disease, rise in pollution level, increasing number of smokers and low cost of manufacturing is encouraging more production facilities in emerging countries will lead to the growth of market in a couple of years.


Aerochamber based segment is anticipated to grow with the highest CAGR of 5.26%

Product segment includes aerochamber, optichamber, volumatic and inspirease. Aerochamber based segment is anticipated to grow with the highest CAGR of 5.26% in the forecast period. Technological advancement and better cross valve technique have encouraged the growth of the segment.

Distribution channel segment is held largest market share of 56.07% in 2017

Industry segment is divided into segments such as retail pharmacy, hospital pharmacy and e-commerce. The e-commerce is playing a chief role in shaping business growth and held the largest share of 56.07% in 2017. Products available on discounted price as compared to hospitals and retailors will lead to the growth of e-commerce segment in future.

Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North America held the largest market share of approximately 41.38% in 2017. Increasing adoption of the device, rise in the prevalence of asthma cases and presence of major manufacturing companies in the region, these are some of the factors that led to the growth of market in this region.


Competitive Analysis:

The major players of market include trudell Medical Internationa, Pari Gmbh, GlaxoSmihKline plc, Medical Development International, Cipla, Lupin, Clement Clarke, AstraZeneca, Merck & Co., Fisons, GlaxoSmithKline Plc., Merck & Co., Inc., 3M, Aristopharma Ltd., SRS PHARMACEUTICALS PVT. LTD., Intas Pharmaceuticals, Ltd, CONMED Corporation, PARI Respiratory Equipment, Inc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, OMRON Healthcare Europe B.V., Teva Pharmaceutical Industries Ltd. and others. Technological advancements are playing major role in the growth of the market. For instance, in 2017, Boehringer Ingelheim Pharmaceuticals, Inc. introduced U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT. It is an inhalation spray and used for the long-term for the treatment of asthma in people age 6 and older.

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.